So­ci­etal nabs sole sup­pli­er role for Ri­tal­in to Eu­rope

Un­til the end of 2023, So­ci­etal will be the sole sup­pli­er of Ri­tal­in to Eu­rope.

The CD­MO an­nounced on Thurs­day that it’s en­tered a three-year man­u­fac­tur­ing and sup­ply deal with In­fec­toPharm for the at­ten­tion deficit hy­per­ac­tiv­i­ty dis­or­der drug to re­main the sole sup­pli­er of the drug through the end of next year. The deal runs through the end of April 2025; So­ci­etal will con­tin­ue sup­ply­ing Ri­tal­in af­ter its ex­clu­siv­i­ty ends next year along with oth­er sup­pli­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER